211 related articles for article (PubMed ID: 38351531)
1. Meta-analysis of microarray data to determine gene indicators involved in cisplatin resistance in non-small cell lung cancer.
Sheikhshabani SH; Modarres P; Ghafouri-Fard S; Amini-Farsani Z; Khodaee L; Shaygan N; Amini-Farsani Z; Omrani MD
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1970. PubMed ID: 38351531
[TBL] [Abstract][Full Text] [Related]
2. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
[TBL] [Abstract][Full Text] [Related]
3. FIGNL1 is a potential biomarker of cisplatin resistance in non-small cell lung cancer.
Meng C; Yang Y; Ren P; Ju Q; Jin X; Long Q; Chen X; Wang X; Li F
Int J Biol Markers; 2022 Sep; 37(3):260-269. PubMed ID: 35791674
[TBL] [Abstract][Full Text] [Related]
4. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
[TBL] [Abstract][Full Text] [Related]
5. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
6. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
7. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.
Deng H; Qianqian G; Ting J; Aimin Y
Biomed Pharmacother; 2018 Oct; 106():1072-1081. PubMed ID: 30119173
[TBL] [Abstract][Full Text] [Related]
8. Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways.
Cui Z; Li D; Zhao J; Chen K
Free Radic Biol Med; 2022 Apr; 183():106-124. PubMed ID: 35278641
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of circular RNA expression profiles in cisplatin-resistant non-small cell lung cancer cell lines.
Song L; Cui Z; Guo X
Acta Biochim Biophys Sin (Shanghai); 2020 Sep; 52(9):944-953. PubMed ID: 32716023
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of non‑small cell lung cancer cell lines.
Suzuki T; Sirimangkalakitti N; Baba A; Toyoshima-Nagasaki R; Enomoto Y; Saito N; Ogasawara Y
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35147203
[TBL] [Abstract][Full Text] [Related]
11. MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway.
Sun DM; Tang BF; Li ZX; Guo HB; Cheng JL; Song PP; Zhao X
Sci Rep; 2018 May; 8(1):8007. PubMed ID: 29789623
[TBL] [Abstract][Full Text] [Related]
12. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
[TBL] [Abstract][Full Text] [Related]
13. GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo-sensitivity of cisplatin in NSCLC cells: bioinformatics analysis and laboratory validation.
Zhao M; Li X; Chen X
J Bioenerg Biomembr; 2021 Apr; 53(2):177-189. PubMed ID: 33538941
[TBL] [Abstract][Full Text] [Related]
14. Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer.
Liu H; Zhu Y; Niu H; Jie J; Hua S; Bai X; Wang S; Song L
Cancer Med; 2023 Oct; 12(19):19777-19793. PubMed ID: 37732632
[TBL] [Abstract][Full Text] [Related]
15. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
[TBL] [Abstract][Full Text] [Related]
16. Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3β/Snail Signaling in Non-Small Cell Lung Cancer.
Li JM; Yang F; Li J; Yuan WQ; Wang H; Luo YQ
Med Sci Monit; 2020 Aug; 26():e925298. PubMed ID: 32764530
[TBL] [Abstract][Full Text] [Related]
17. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways.
Zhu B; Ren C; Du K; Zhu H; Ai Y; Kang F; Luo Y; Liu W; Wang L; Xu Y; Jiang X; Zhang Y
Biochem Pharmacol; 2019 Dec; 170():113642. PubMed ID: 31541631
[TBL] [Abstract][Full Text] [Related]
18. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
19. Circular RNA hsa_circ_0068252 Functions in Cisplatin Resistance and Immune Response via miR-1304-5p/PD-L1 Axis in Non-Small Cell Lung Cancer.
Li J; Xu J; Wu G; Ren Y; Wang X; Zhang Q
Chemotherapy; 2022; 67(4):223-233. PubMed ID: 35649347
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]